These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30484960)

  • 1. Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy-A nationwide study in patients with osteoarthritis.
    Barcella CA; Lamberts M; McGettigan P; Fosbøl EL; Lindhardsen J; Torp-Pedersen C; Gislason GH; Olsen AS
    Basic Clin Pharmacol Toxicol; 2019 May; 124(5):629-641. PubMed ID: 30484960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk of fatal/non-fatal events in patients with previous coronary heart disease/acute myocardial infarction and treatment with non-steroidal anti-inflammatory drugs].
    Muñoz Olmo L; Juan Armas J; Gomariz García JJ
    Semergen; 2018; 44(5):355-363. PubMed ID: 28882733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study.
    Olsen AM; Fosbøl EL; Lindhardsen J; Andersson C; Folke F; Nielsen MB; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
    PLoS One; 2013; 8(1):e54309. PubMed ID: 23382889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
    Solomon DH; Husni ME; Wolski KE; Wisniewski LM; Borer JS; Graham DY; Libby P; Lincoff AM; Lüscher TF; Menon V; Yeomans ND; Wang Q; Bao W; Berger MF; Nissen SE;
    Arthritis Rheumatol; 2018 Apr; 70(4):537-546. PubMed ID: 29266879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
    Schjerning Olsen AM; Fosbøl EL; Lindhardsen J; Folke F; Charlot M; Selmer C; Lamberts M; Bjerring Olesen J; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
    Circulation; 2011 May; 123(20):2226-35. PubMed ID: 21555710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure.
    Bally M; Beauchamp ME; Abrahamowicz M; Nadeau L; Brophy JM
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):69-77. PubMed ID: 29171096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction.
    Lamberts M; Fosbøl EL; Olsen AM; Hansen ML; Folke F; Kristensen SL; Olesen JB; Hansen PR; Køber L; Torp-Pedersen C; Gislason GH
    Int J Cardiol; 2013 Sep; 168(2):832-7. PubMed ID: 23117013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Cunnington M; Webb D; Qizilbash N; Blum D; Mander A; Funk MJ; Weil J
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):601-8. PubMed ID: 18383442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
    Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
    Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.
    Sondergaard KB; Weeke P; Wissenberg M; Schjerning Olsen AM; Fosbol EL; Lippert FK; Torp-Pedersen C; Gislason GH; Folke F
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):100-107. PubMed ID: 28025218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diclofenac use and cardiovascular risks: series of nationwide cohort studies.
    Schmidt M; Sørensen HT; Pedersen L
    BMJ; 2018 Sep; 362():k3426. PubMed ID: 30181258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study.
    Bech-Drewes A; Bonnesen K; Hauge EM; Schmidt M
    Rheumatol Int; 2024 Jun; 44(6):1061-1069. PubMed ID: 38581450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
    Schmidt M; Hallas J; Ernst MT; Pottegård A
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):562-569. PubMed ID: 37385823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.